Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G2030 - Common Stock

0.828  +0 (+0.31%)

After market: 0.7853 -0.04 (-5.16%)

Fundamental Rating

2

Taking everything into account, SXTP scores 2 out of 10 in our fundamental rating. SXTP was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of SXTP is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SXTP had negative earnings in the past year.
SXTP had a negative operating cash flow in the past year.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -113.00%, SXTP is not doing good in the industry: 79.03% of the companies in the same industry are doing better.
With a Return On Equity value of -138.85%, SXTP is not doing good in the industry: 63.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROIC N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

SXTP has a Gross Margin of 10.73%. This is comparable to the rest of the industry: SXTP outperforms 48.39% of its industry peers.
SXTP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
The debt/assets ratio for SXTP has been reduced compared to a year ago.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M 5M
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -9.71. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
SXTP has a Altman-Z score of -9.71. This is in the lower half of the industry: SXTP underperforms 74.73% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that SXTP is not too dependend on debt financing.
SXTP has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -9.71
ROIC/WACCN/A
WACC3.39%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 5.26 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a better Current ratio (5.26) than 66.67% of its industry peers.
SXTP has a Quick Ratio of 4.91. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
SXTP's Quick ratio of 4.91 is fine compared to the rest of the industry. SXTP outperforms 66.13% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 4.91
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

SXTP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -230.74%.
The Revenue for SXTP has decreased by -35.93% in the past year. This is quite bad
SXTP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.20% yearly.
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.06%
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5YN/A
Sales Q2Q%164.71%

3.2 Future

Based on estimates for the next years, SXTP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.42% on average per year.
SXTP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 151.54% yearly.
EPS Next Y54.66%
EPS Next 2Y35.85%
EPS Next 3Y25.42%
EPS Next 5YN/A
Revenue Next Year151.05%
Revenue Next 2Y162.83%
Revenue Next 3Y151.54%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SXTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SXTP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.85%
EPS Next 3Y25.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SXTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (1/17/2025, 8:00:01 PM)

After market: 0.7853 -0.04 (-5.16%)

0.828

+0 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/dmh
Earnings (Next)N/A N/A
Inst Owners3.02%
Inst Owner Change0%
Ins Owners10.41%
Ins Owner Change6.3%
Market Cap1.90M
Analysts80
Price Target3.47 (319.08%)
Short Float %8.12%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.85%
Min EPS beat(2)-48.37%
Max EPS beat(2)-29.33%
EPS beat(4)1
Avg EPS beat(4)-7.57%
Min EPS beat(4)-72.17%
Max EPS beat(4)119.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-43.68%
Min Revenue beat(2)-45.31%
Max Revenue beat(2)-42.06%
Revenue beat(4)0
Avg Revenue beat(4)-35.64%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-11.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-38.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-633.33%
EPS NY rev (1m)0%
EPS NY rev (3m)17.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.12
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-9.12
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0.2
BVpS2.63
TBVpS2.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.73%
FCFM N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 549.4%
Cap/Sales 53.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 4.91
Altman-Z -9.71
F-Score3
WACC3.39%
ROIC/WACCN/A
Cap/Depr(3y)176.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.06%
EPS Next Y54.66%
EPS Next 2Y35.85%
EPS Next 3Y25.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5YN/A
Sales Q2Q%164.71%
Revenue Next Year151.05%
Revenue Next 2Y162.83%
Revenue Next 3Y151.54%
Revenue Next 5YN/A
EBIT growth 1Y-90.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-335.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-349.8%
OCF growth 3YN/A
OCF growth 5YN/A